BioSpace News Archive

Business

ChromaDex to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

ChromaDex Corp. announced that it will hold a conference call on Tues., Nov. 12, 2019 at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sept. 30, 2019.

November 4, 2019
·
3 min read
Job Trends

New Nephrology Care Alliance empowers physicians to Deliver Value-Based Care to Patients with Kidney Disease

Chief Medical Officer, Dr. Leslie Wong, to Join Alliance as Clinical Leader

November 4, 2019
·
2 min read
Business

PhoreMost and Sentinel Oncology Expand Collaboration to Jointly Accelerate Novel Glioma Therapeutic Through Preclinical Development

Lead allosteric PLK1 inhibitor to progress through preclinical and IND enabling studies

November 4, 2019
·
2 min read
Business

Trevena Reports Third Quarter 2019 Results and Topline Data From Multi-Dose Healthy Volunteer QT Study

Trevena, Inc. announced topline results from its multi-dose QT study for IV oliceridine, reported its financial results for the third quarter ended September 30, 2019, and provided an overview of its recent operational highlights.

November 4, 2019
·
10 min read
RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare

Pluristem Therapeutics Inc., a leading regenerative medicine company developing novel placenta-based cell therapy products, announced that the RESTORE Consortium is hosting its 1st Advanced Therapies Science Meeting, which is being held November 25-26, 2019 in Berlin.

November 4, 2019
·
6 min read
Business

Elysium Health™ Announces Head of Bioinformatics and the Launch of INDEX by Elysium Health

A powerful measure of overall health and wellness that enables customers to test their cumulative rate of aging and biological age--the average age at which their body is expected to perform

November 4, 2019
·
4 min read
Drug Development

MAX BioPharma Announces Key Update to its Oncology Program and Oxysterol Lead Drug Candidates that Target Tumorigenic Signaling Pathways

MAX BioPharma is Pursuing Strategic Partnerships and Series A Financing

November 4, 2019
·
4 min read
Drug Development

First Patient Screened for RhoVac’s Clinical Phase IIb-study

RhoVac AB announces, on 4th November 2019, that the first patient has been screened for the company’s clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 The screening took place at the Odense University Hospital.

November 4, 2019
·
2 min read
Össur and Alfred Mann Foundation Sign New Agreement to Extend Exploration of Mind-Controlled Prosthetics

The Organizations are Collaborating on Implanted Myoelectric Sensors to Control Bionic Prosthetic Limbs

November 4, 2019
·
3 min read
Biotech Bay

PQ Bypass Initiates Pivotal Study of Next-Generation Advancement in Stent Graft Technology for Treatment of Patients with Peripheral Artery Disease

PQ Bypass, Inc. announced it has enrolled the first patient in its TORUS 2 multi-center clinical trial of its self-expanding TORUS® stent graft system, a novel technology designed for the treatment of peripheral artery disease in the superficial femoral artery This inaugural enrollment comes less than a month after the study received unconditional approval from the FDA for the TORUS 2 original IDE.

November 4, 2019
·
4 min read